Godavari Drugs Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Godavari Drugs Ltd is ₹ 124.95 as of 05 May 15:30 . The P/E Ratio of Godavari Drugs Ltd is 0 as of December 2023 .The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 . The Market Cap of Godavari Drugs Ltd is ₹ 0 crore as of December 2023 .The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 . The Revenue of Godavari Drugs Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Godavari Drugs Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Godavari Drugs Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The dividend payout of Godavari Drugs Ltd changed from 0 % to 0 % over 10 quarters. This represents a CAGR of 0.0% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% .

About Godavari Drugs Ltd

Godavari Drugs Limited is engaged in the business of manufacture of Active Pharmaceutical Ingredients (API) and drug intermediates, through its manufacturing facility at Nanded, Maharashtra, India..
Sulphamethoxazole (SMX), the main product of the company, is a widely used anti-bacterial drug enjoying good export demand. The Company incorporated in December, 1987, has multiple production blocks for API's, drug intermediates and fine chemicals. The company has expanded its SMX capacity from 540 tpa to 720 tpa, integrating backward into the manufacture of drug intermediates, sulphamethoxide (cap.: 450 tpa) and diethyl oxalate, DEO (cap.: 750 tpa), and diversifying into the manufacture of trimetroprim, TMP (cap.: 144 tpa). The diversification into TMP is beneficial as SMX and TMP are used in combination to treat a wide variety of infections.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Godavari Drugs Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Godavari Drugs Ltd or Sanofi India Ltd?

Market cap of Godavari Drugs Ltd is 127 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Godavari Drugs Ltd and Sanofi India Ltd?

The stock performance of Godavari Drugs Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Godavari Drugs Ltd and Sanofi India Ltd?

As of May 5, 2026, the Godavari Drugs Ltd stock price is INR ₹125.8. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Godavari Drugs Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Godavari Drugs Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.